Dipeptide variants of alafosfalin (L-alanyl-L-1-aminoethylphosphonic acid) with substantial differences in potency and antibacterial spectrum in vitro and in vivo have been synthesized. Certain dipeptides with alternptives to the L-alanyl residue had broader antibacterial spectra; activity against Pseudomonas aeruginosa was included. Some compounds had better in vivo activity than alafosfalin when introduced into infected rodents orally, but for the majority of the more active phosphonodipeptides, parenteral administration was more effective. Certain oligopeptides derived from the more active phosphonodipeptides possessed good in vitro activity against an extended range of organisms; they included Haemophilus influenzae, Streptococcus faecalis, and Streptococcus pneumoniae. The in vivo activity of some of these phosphono-oligopeptides was significantly greater than that of the parent dipeptide and correlated well with the in vitro results. This indicates that phosphono-oligopeptides exert part of their in vivo action directly, in addition to that arising from smaller peptides produced by peptidase cleavage.Phosphonopeptides constitute a class of synthetic antibacterial peptide mimetics in which the C-terminal carboxyl group has been replaced by a phosphoryl [P(O) (OH)2] function (1). These compounds are transported into bacteria by means of peptide permeases located in the bacterial cytoplasmic membrane. Within the cell they are cleaved enzymatically to liberate an aminoalkylphosphonic acid moiety which inhibits cell wall biosynthesis (3). In a previous study, phosphonopeptides containing L-amino acids linked to the L-1-aminoethylphosphonic acid Ala(P) [or less significantly, to aminomethylphosphonic acid, Gly(P)] as the acid terminal substituent were shown to forin the most interesting series of compounds (4). On the basis of antibacterial activity in vitro and in vivo and stability to mammalian peptide hydrolase enzymes, alafosfalin [L-alanyl-L-1-aminoethylphosphonic acid; Ala-Ala(P)] was selected for detailed evaluation (1-4). (All amino acids and amino acid mimetics in this paper are of the L series, and L-is therefore omitted in abbreviations.)Although alafosfalin had high levels of activity against certain members of the Enterobacteriaceae, including Enterobacter sp., Escherichia coli, Klebsiella sp., and Shigella sp., the antibacterial activity against Proteus and Pseudomonas spp. or streptococci (with the exception of Streptococcus faecalis) was modest (1, 2, 4). However, as the investigation of the mechanism of action of this new class of antibacterial agents developed, it appeared likely that phosphonopeptides with advantages over alafosfalin might be identified. This has been confirmed.In our preliminary studies (4) we observed that certain phosphonodipeptides with different natural amino acids combined with Ala(P) showed very substantial differences in antibacterial activity. A detailed investigation of L-methionyl (Met)-Ala(P) established that the enhanced activity and broader antibacterial spectrum...